期刊文献+

CD39-CD73-腺苷通路在肝细胞癌免疫调控中的研究进展

Research progress of CD39-CD73-adenosine pathway in immune regulation of hepatocellular carcinoma
下载PDF
导出
摘要 肝细胞癌(hepatocellular carcinoma,HCC)患者占原发性肝癌患者总数的85%~90%。以切除术和肝移植术为代表的手术治疗疗效较好,是目前HCC首选治疗方法,患者治疗后5年生存率为70%~80%。然而,HCC的高复发率仍是目前肝癌治疗的难点。由于HCC存在异质性,现有化疗药物和多激酶抑制剂疗效有限,研究新的治疗策略至关重要。CD39-CD73-腺苷通路通过将促炎的细胞外三磷酸腺苷(extracellular adenosine triphosphate,eATP)转化为免疫抑制性腺苷,在肝脏微环境中发挥调控作用。靶向该通路中的关键分子进行治疗有抗肿瘤效果。靶向CD39-CD73-腺苷通路或以该通路为基础的联合治疗策略可能为HCC患者提供更有效的治疗选择。本文对CD39-CD73-腺苷通路在HCC中的生物学效应及其免疫调控作用作一综述。 Hepatocellular carcinoma(HCC)patients accounts for 85%-90%of all primary liver cancer patients.Surgical treatment methods,represented by resection and liver transplantation,have relatively good efficacy and are currently the preferred treatment approaches for HCC,with a 5-year survival rate of 70%-80%after treatment.However,the high recurrence rate of HCC remains the greatest challenge in current liver cancer treatment.Due to the heterogeneity of HCC,the efficacy of current chemotherapy drugs and multi-kinase inhibitors is limited.It is crucial to explore new therapeutic strategies.The CD39-CD73-adenosine pathway plays a significant regulatory role in the liver microenvironment by converting pro-inflammatory extracellular adenosine triphosphate(eATP)into immunosuppressive adenosine.Targeting key molecules in this pathway for treatment has shown anti-tumor effects.Strategies of targeting the CD39-CD73-adenosine pathway and combined therapeutic strategies based on the CD39-CD73-adenosine pathway might offer more effective treatment options for HCC patients.This article reviews the biological effects and roles of the CD39-CD73-adenosine pathway in the immune regulation of HCC.
作者 孙林 王蓓丽 郭玮 SUN Lin;WANG Beili;GUO Wei(Department of Laboratory Medicine,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处 《中国临床医学》 2024年第6期1000-1005,共6页 Chinese Journal of Clinical Medicine
基金 国家自然科学基金(81972000、82172348、81902139) 上海市临床重点专科建设项目(shslczdzk03302) 厦门市医疗卫生重点项目(YDZX20193502000002) 上海市宝山区医学重点专科(BSZK-2023-A18) 复旦大学附属中山医院临床研究专项基金(2020ZSLC54) 复旦大学附属中山医院优秀骨干计划(2021ZSGG08).
关键词 肝细胞癌 免疫调控 CD39 CD73 腺苷通路 hepatocellular carcinoma immune regulation CD39 CD73 adenosine pathway
  • 相关文献

参考文献3

二级参考文献3

共引文献553

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部